JEFFERY DAVIS: Open Payments
NPI 1639402738 · CREVE COEUR, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,075 in 66 payments from 12 companies in 2025. Trend: 2023 $6,242 · 2024 $12,391 · 2025 $3,075
Food & beverage: $1,727Speaker / faculty: $1,170Education: $138Travel & lodging: $41
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. | 4 | $1,261 |
| Teva Pharmaceuticals USA, Inc. | 21 | $474 |
| Neurocrine BioSciences, Inc. | 7 | $335 |
| Otsuka America Pharmaceutical, Inc. | 8 | $259 |
| Alpha Cognition USA, Inc. | 2 | $246 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $140 |
| Alkermes, Inc. | 5 | $106 |
| ACADIA Pharmaceuticals Inc | 3 | $62 |
| E.R. Squibb & Sons, L.L.C. | 3 | $55 |
| Lundbeck LLC | 2 | $53 |
Products named: Nayzilam, INGREZZA, REXULTI, Zunveyl, AUSTEDO XR, UZEDY, CAPLYTA, ARISTADA.
Industry payments across MO — which companies pay providers there.
